• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Eli Lilly

Eli Lilly

Principal Large Cap Growth R3 PLGPX 2 Star

Last Price$9.79Day Change (%)-1.61%
Open Price$9.79Day Change ($)-0.16
Day Range9.79–9.7952-Week Range8.84–11.88

As of Fri 12/01/2016 | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. The Corporate Reputation of Pharma 2015-2016 - The Perspective of 139 Patient Groups with an Interest in Diabetes - Research and Markets

    The Corporate Reputation of Pharma 2015-2016 - The Perspective of 139 Patient Groups with an Interest in Diabetes - Research and Markets

  2. Eli Lilly shares slide premarket after company says Alzheimer's drug trial failed

    Eli Lilly shares slide premarket after company says Alzheimer's drug trial failed

  3. Eli Lilly's Alzheimer's Drug Trial Fails to Achieve Goals

    Eli Lilly's Alzheimer's Drug Trial Fails to Achieve Goals

  4. Eli Lilly's Setback Highlights Challenges of Alzheimer's Treatment

    Eli Lilly's Setback Highlights Challenges of Alzheimer's Treatment

  5. Eli Lilly's Late Stage Alzheimer's Trial Fails To Achieve Goal -- 2nd Update

    Eli Lilly's Late Stage Alzheimer's Trial Fails To Achieve Goal -- 2nd Update

  6. UPDATE: Biogen in promising but risky limelight after Eli Lilly's Alzheimer's drug fails

    UPDATE: Biogen in promising but risky limelight after Eli Lilly's Alzheimer's drug fails

  7. Biogen in promising but risky limelight after Eli Lilly's Alzheimer's drug fails

    Biogen in promising but risky limelight after Eli Lilly's Alzheimer's drug fails

  8. UPDATE: What Eli Lilly's hard fall in Alzheimer's treatment race means for its competitors

    UPDATE: What Eli Lilly's hard fall in Alzheimer's treatment race means for its competitors

  9. UPDATE: What Eli Lilly's hard fall in Alzheimer's treatment race means for its competitors

    UPDATE: What Eli Lilly's hard fall in Alzheimer's treatment race means for its competitors

  10. UPDATE: What Eli Lilly's hard fall in Alzheimer's treatment race means for its competitors

    UPDATE: What Eli Lilly's hard fall in Alzheimer's treatment race means for its competitors

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.